Abstract
The clinical dosage formulation of Paclitaxel and Docetaxel, Taxol® and Taxotere®, while having high efficacy, can cause serious side effects due to the adjuvant used. We have developed a system of nanoparticles (NPs) of biodegradable copolymer, poly(lactic acid)-d-α-tocopheryl polyethylene glycol 1000 succinate (PLA-TPGS), for Docetaxel formulation to achieve enhanced, sustainable and controlled chemotherapeutic effectiveness and reduce the undesirable side actions. Docetaxel-loaded PLA-TPGS NPs were synthesized with desired size and physicochemical and pharmaceutical properties. In vitro studies using MCF-7 cancer cells have demonstrated the higher cellular uptake and therapeutic effects of the NP formulation. In vivo pharmacokinetics and biodistribution analysis have shown that one dose of the NP formulation of Docetaxel can achieve a 360-h effective chemotherapy with 3.44-fold higher therapeutic effect and 4.42-fold lower side effect than that of Taxotere® at the same dose of 10 mg/kg, as indicated by the larger area-under-the-curve and better biodistribution.
Keywords: Anticancer drugs, biodegradable polymers, cancer nanotechnology, chemotherapeutic engineering, nanomedicine
Current Pharmaceutical Design
Title: Nanomedicine: Enhancement of Chemotherapeutical Efficacy of Docetaxel by Using a Biodegradable Nanoparticle Formulation
Volume: 16 Issue: 21
Author(s): Chee Wee Gan, Shu Chien and Si-Shen Feng
Affiliation:
Keywords: Anticancer drugs, biodegradable polymers, cancer nanotechnology, chemotherapeutic engineering, nanomedicine
Abstract: The clinical dosage formulation of Paclitaxel and Docetaxel, Taxol® and Taxotere®, while having high efficacy, can cause serious side effects due to the adjuvant used. We have developed a system of nanoparticles (NPs) of biodegradable copolymer, poly(lactic acid)-d-α-tocopheryl polyethylene glycol 1000 succinate (PLA-TPGS), for Docetaxel formulation to achieve enhanced, sustainable and controlled chemotherapeutic effectiveness and reduce the undesirable side actions. Docetaxel-loaded PLA-TPGS NPs were synthesized with desired size and physicochemical and pharmaceutical properties. In vitro studies using MCF-7 cancer cells have demonstrated the higher cellular uptake and therapeutic effects of the NP formulation. In vivo pharmacokinetics and biodistribution analysis have shown that one dose of the NP formulation of Docetaxel can achieve a 360-h effective chemotherapy with 3.44-fold higher therapeutic effect and 4.42-fold lower side effect than that of Taxotere® at the same dose of 10 mg/kg, as indicated by the larger area-under-the-curve and better biodistribution.
Export Options
About this article
Cite this article as:
Wee Gan Chee, Chien Shu and Feng Si-Shen, Nanomedicine: Enhancement of Chemotherapeutical Efficacy of Docetaxel by Using a Biodegradable Nanoparticle Formulation, Current Pharmaceutical Design 2010; 16 (21) . https://dx.doi.org/10.2174/138161210791920487
DOI https://dx.doi.org/10.2174/138161210791920487 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Upregulation of Focal Adhesion Kinase by 14-3-3ε via NFκB Activation in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Mitosis-Targeting Natural Products for Cancer Prevention and Therapy
Current Drug Targets Ovarian Cancer Biomarkers: Headway Towards Early Diagnosis
Current Chemical Biology A Review on Targeting Nanoparticles for Breast Cancer
Current Pharmaceutical Biotechnology Anticancer Effect of Amygdalin (Vitamin B-17) on Hepatocellular Carcinoma Cell Line (HepG2) in the Presence and Absence of Zinc
Anti-Cancer Agents in Medicinal Chemistry Triterpene Derivatives as Inhibitors of Protein Involved in the Inflammatory Process: Molecules Interfering with Phospholipase A2, Cycloxygenase, and Lipoxygenase
Current Drug Targets Identifying Breast Cancer-induced Gene Perturbations and its Application in Guiding Drug Repurposing
Current Bioinformatics Central Nervous System Disorders Associated to Immune Checkpoint Inhibitors
Current Cancer Therapy Reviews Targeting Microparticle Biogenesis: A Novel Approach to the Circumvention of Cancer Multidrug Resistance
Current Cancer Drug Targets Dexmedetomidine Use in General Anaesthesia
Current Drug Targets Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design Endomorphin Derivatives with Improved Pharmacological Properties
Current Medicinal Chemistry Gene Silencing in the Development of Personalized Cancer Treatment: The Targets, the Agents and the Delivery Systems
Current Gene Therapy Rho Kinase and Angiogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Development and Engineering of Lymphatic Endothelial Cells: Clinical Implications
Current Pharmaceutical Design Application of Phage Display Technology to Cancer Research
Current Pharmaceutical Biotechnology Mitochondria as Possible Pharmaceutical Targets for the Effects of Vitamin E and its Homologues in Oxidative Stress-Related Diseases
Current Pharmaceutical Design Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells May be Induced by Interactions Between Receptor Tyrosine Kinases and ERα-66
Recent Patents on Anti-Cancer Drug Discovery Regulation of Tumor Angiogenesis by the Immune System
Current Angiogenesis (Discontinued) Importance of ABC Transporters in Drug Development
Current Pharmaceutical Design